Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Wave Life Sci Ord Sh (NQ: WVE )

8.610 +0.350 (+4.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Wave Life Sci Ord Sh

< Previous 1 2 3 4 5 6 7 Next >
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
WAVE Life Sciences's Earnings Outlook
Via Benzinga
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
Analyst Ratings for WAVE Life Sciences
Via Benzinga
WAVE Life Sciences's Return On Capital Employed Overview
Via Benzinga
Earnings Scheduled For November 9, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million. 
Via Benzinga
Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Recap: WAVE Life Sciences Q1 Earnings
Via Benzinga
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
2 Cutting-Edge Gene-Editing Stocks That You Don't Want to Miss
The gene-editing market is moving fast, and it pays to get to know some of these companies. 
Via The Motley Fool
Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
7 A-Rated Biotech Stocks for Your August Buy List
Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge. 
Via InvestorPlace
Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Analyst Creates Bullish Pitch For WAVE Life Sciences, Says It Is 'Leader To Clinic In RNA Editing'
Raymond James has initiated coverage on WAVE Life Sciences Ltd (NASDAQ: WVE) with a price target of $9 and  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023
Via Benzinga
Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods. 
Via Benzinga
Wave Life Sciences' Stock Falls: Investigational Therapy Fails To Show Clinical Benefit In Rare Neurological Diseases
Wave Life Sciences Ltd (NASDAQ: WVE) announced topline results from the Phase 1b/2a FOCUS-C9 study evaluating WVE-004 as an investigational treatment for C9orf72-associated amyotrophic lateral... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual Meeting
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Estee Lauder, NerdWallet, Sprout Social And Other Big Stocks Moving Lower On Wednesday
U.S. stocks mostly traded higher, but the Dow Jones lost around 19 points on Wednesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.